Know AML webinar | Closing remarks and Q&A

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience addressed by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK; Gail J. Roboz, Weill Cornell Medicine, New York, US; and Ralph Hills, Connecticut, US.

Craddock shared key takeaways from the webinar, emphasizing:

• The role of mutation testing in diagnosing AML, identifying subtypes and risks, and in guiding treatment decisions, both within and outside a clinical trial

• The importance of selecting the most appropriate method for testing mutations

• The value of open and clear communication between physicians and patients to make decisions together

The speakers then addressed questions from the audience.

This independent educational activity is supported by Thermo Fisher Scientific.
All content was developed independently by the faculty. The funder was allowed no influence on the content.